The global TAM for treatment of diabetes is massive. US equity markets have a lot of experience valuing continuous glucose monitoring (CGM) device makers such as the market leader, Dexcom (NYSE; DXCM);
- The global TAM for CGM device makers is c. US$5bn with cagr c.11%.
- DXCM current mkt value = US$35bn, equating to a revenue multiple of about x35!!!
- The point is, US equity markets go bananas over diabetes treatment innovation due to huge TAM, cagr and IP protection.
For the treatment of DFU's;
- TAM of US$7bn and likely c.10% cagr
- The application of Synpath to DFU's is a sleeping giant under the sp of PNV.
- Forums
- ASX - By Stock
- PNV
- Ann: First Patient enrolled - SynPath Diabetic Foot Ulcer Trial
Ann: First Patient enrolled - SynPath Diabetic Foot Ulcer Trial, page-51
Featured News
Add PNV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$2.38 |
Change
-0.030(1.24%) |
Mkt cap ! $1.642B |
Open | High | Low | Value | Volume |
$2.42 | $2.44 | $2.36 | $4.288M | 1.798M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 28177 | $2.37 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.38 | 26895 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2525 | 2.360 |
6 | 28060 | 2.350 |
2 | 2993 | 2.340 |
2 | 3602 | 2.330 |
1 | 2102 | 2.320 |
Price($) | Vol. | No. |
---|---|---|
2.400 | 2525 | 1 |
2.410 | 2525 | 1 |
2.420 | 19143 | 4 |
2.430 | 2525 | 1 |
2.440 | 14572 | 4 |
Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
Featured News
PNV (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online